Medications That Increase Oxycodone Bioavailability
CYP3A4 inhibitors significantly increase oxycodone plasma concentrations and bioavailability, potentially causing life-threatening respiratory depression.
Primary Drug Interactions: CYP3A4 Inhibitors
The FDA label explicitly warns that concomitant use of oxycodone with CYP3A4 inhibitors increases plasma concentrations of oxycodone and prolongs opioid adverse reactions, which may cause potentially fatal respiratory depression 1. The specific drug classes that increase oxycodone bioavailability include:
High-Risk CYP3A4 Inhibitors:
- Macrolide antibiotics (e.g., erythromycin, clarithromycin)
- Azole antifungal agents (e.g., ketoconazole, itraconazole, fluconazole)
- Protease inhibitors (e.g., ritonavir, indinavir)
These medications work by inhibiting the CYP3A4 enzyme system, which is the major metabolic pathway for oxycodone 1, 2. When this pathway is blocked, oxycodone accumulates to higher concentrations and remains in the system longer.
Clinical Management Algorithm
When initiating a CYP3A4 inhibitor in a patient on stable oxycodone:
- Monitor the patient closely at frequent intervals
- Consider dosage reduction of oxycodone until stable drug effects are achieved
- Watch specifically for respiratory depression, excessive sedation, and other opioid toxicity signs 1
When discontinuing a CYP3A4 inducer (such as rifampin, carbamazepine, or phenytoin) in oxycodone-treated patients, the same risk applies—oxycodone concentrations will increase as the inducing effect wears off 1.
Important Caveats
The CYP2D6 Pathway
While CYP2D6 is a minor metabolic pathway for oxycodone (converting it to oxymorphone), simultaneous inhibition of both CYP3A4 and CYP2D6 results in the highest oxycodone concentrations and should be avoided 2. This combination creates a particularly dangerous scenario.
CNS Depressants Are Not Bioavailability Enhancers
Benzodiazepines, alcohol, and other CNS depressants do not increase oxycodone bioavailability—they add pharmacodynamic effects that compound respiratory depression risk through different mechanisms 1. This is a critical distinction.
Magnesium Actually Decreases Bioavailability
Contrary to what might be expected, micronized magnesium lactate decreases oxycodone bioavailability due to chemical reactions between formulation components 3. This is clinically relevant when patients take magnesium supplements or antacids.
Practical Monitoring
Oxycodone has 60-87% oral bioavailability under normal circumstances, which is already higher than morphine 1, 2. When CYP3A4 inhibitors are added, this can increase substantially. The FDA specifically states to monitor patients closely at frequent intervals when these combinations cannot be avoided 1.
The risk is greatest during:
- The first 24-72 hours after initiating the CYP3A4 inhibitor
- Any dose increase of either medication
- In patients who are CYP2D6 poor metabolizers receiving a CYP3A4 inhibitor (double metabolic blockade) 2
The bottom line: Avoid CYP3A4 inhibitors in patients on oxycodone whenever possible. When unavoidable, reduce oxycodone dose preemptively and monitor intensively for respiratory depression.